An Observational Registry of Abatacept in Patients With Juvenile Idiopathic Arthritis

To be part of this study, a child or teenager must have been diagnosed with Juvenile Idiopathic Arthritis (JIA). They also need to be under 18 years old when they join, unless they've been in another Abatacept study before.

Crucially, they must already be taking Abatacept for their JIA, either because their doctor decided it was the best treatment for them, or because they received it in an earlier study. A parent or legal guardian must be happy for them to take part and sign a consent form.

However, some children won't be able to join. This includes girls who are pregnant or breastfeeding. Also, anyone who has had certain types of cancer in the past five years, or has another serious ongoing health problem (apart from their JIA), especially a long-term infection, cannot participate. Finally, if it's known that a patient often misses clinic appointments, they won't be suitable for this study.

This is an observational study, so you generally won't be given new medicine or treatments as part of the study itself. Instead, the doctors will simply collect information about your child's health and the Abatacept they are already receiving from their own doctor. This means attending regular check-ups as recommended by your child's treating physician, just as you normally would. At these visits, the study team will collect data from your child's medical records. The total duration of participation isn't specified, but as it's a long-term safety study, it will likely involve collecting data over an extended period.